AR058621A1 - Metodods para reducir la proteina c reactiva - Google Patents

Metodods para reducir la proteina c reactiva

Info

Publication number
AR058621A1
AR058621A1 ARP060105728A ARP060105728A AR058621A1 AR 058621 A1 AR058621 A1 AR 058621A1 AR P060105728 A ARP060105728 A AR P060105728A AR P060105728 A ARP060105728 A AR P060105728A AR 058621 A1 AR058621 A1 AR 058621A1
Authority
AR
Argentina
Prior art keywords
reactive protein
methods
reduce reactive
reduce
level
Prior art date
Application number
ARP060105728A
Other languages
English (en)
Original Assignee
Coca Cola Co
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coca Cola Co, Univ California filed Critical Coca Cola Co
Publication of AR058621A1 publication Critical patent/AR058621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un método para reducir el nivel de proteína C reactiva que comprende la administracion a un sujeto que lo necesite de al menos un fitosterol en una cantidad efectiva para reducir el nivel de proteína C reactiva. Reivindicacion 4: El método de conformidad con la reivindicacion 3, donde la composicion es escogida entre una composicion farmacéutica y un producto consumible.
ARP060105728A 2005-12-23 2006-12-21 Metodods para reducir la proteina c reactiva AR058621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/315,206 US20070003600A1 (en) 2003-06-11 2005-12-23 Methods for reducing c-reactive protein

Publications (1)

Publication Number Publication Date
AR058621A1 true AR058621A1 (es) 2008-02-13

Family

ID=37907825

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105728A AR058621A1 (es) 2005-12-23 2006-12-21 Metodods para reducir la proteina c reactiva

Country Status (11)

Country Link
US (1) US20070003600A1 (es)
EP (1) EP1962858A1 (es)
JP (1) JP2009521495A (es)
KR (1) KR20080090457A (es)
AR (1) AR058621A1 (es)
AU (1) AU2006330626A1 (es)
BR (1) BRPI0620417A2 (es)
CA (1) CA2633993A1 (es)
RU (1) RU2008128316A (es)
TW (1) TW200800046A (es)
WO (1) WO2007076387A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9817001B2 (en) * 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
EP3324184A1 (en) 2011-10-13 2018-05-23 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259915A (en) * 1985-10-09 1989-09-26 Sailen S. Mookerjea Means to reduce plasma cholesterol
US20030104035A1 (en) * 1996-08-09 2003-06-05 Raisio Benecol Ltd. Stanol composition and the use thereof
FI105887B (fi) * 1996-09-27 2000-10-31 Suomen Sokeri Oy Elintarvike- ja terapeuttisiin sovelluksiin käyttökelpoiset, kasvisterolia sisältävät tuotteet, menetelmä niiden valmistamiseksi ja niiden käyttö
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis
US6063776A (en) * 1998-05-26 2000-05-16 Washington University Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6353003B1 (en) * 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6274574B1 (en) * 1999-02-26 2001-08-14 Kraft Foods, Inc. Use of mesophase-stabilized compositions for delivery of cholesterol-reducing sterols and stanols in food products
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US6267963B1 (en) * 1999-06-02 2001-07-31 Kraft Foods, Inc. Plant sterol-emulsifier complexes
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR20020026053A (ko) * 2000-09-30 2002-04-06 노승권 음료용 식물성 스테롤의 분산방법 및 이를 함유하는 음료
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
MXPA04002572A (es) * 2001-09-21 2004-05-31 Schering Corp Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol.
US6646144B1 (en) * 2002-11-04 2003-11-11 Zenitech Llc Dimethicone copolyol cranberriate as a delivery system for natural antioxidants
US20060233863A1 (en) * 2003-02-10 2006-10-19 Enzymotec Ltd. Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements
US8075910B2 (en) * 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
US20060172012A1 (en) * 2005-01-28 2006-08-03 Finley John W Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks

Also Published As

Publication number Publication date
BRPI0620417A2 (pt) 2018-04-10
AU2006330626A1 (en) 2007-07-05
JP2009521495A (ja) 2009-06-04
CA2633993A1 (en) 2007-07-05
US20070003600A1 (en) 2007-01-04
KR20080090457A (ko) 2008-10-08
RU2008128316A (ru) 2010-01-27
WO2007076387A1 (en) 2007-07-05
TW200800046A (en) 2008-01-01
EP1962858A1 (en) 2008-09-03

Similar Documents

Publication Publication Date Title
ES2575152T3 (es) Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
AR056816A1 (es) Composicion con ácido docosapentenoico
AR051397A1 (es) Composicion farmaceutica
WO2006105112A3 (en) Amino acid-containing composition for preventing or remedying in the skeletal muscle of aged people
ES2478820T3 (es) Tratamiento de degeneración macular
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
RS51569B (en) COMPOSITIONS CONTAINING CRYSTAL TRANS - (+/-) - DELTA-9-TETRAHYDROCANABINOL
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
GT200600135A (es) Forma cristalina ortorrombica del maleato de asenapina y su uso en el tratamiento de trastornos mentales
TW200600111A (en) Improved dental whitening method
AR048771A1 (es) Composiciones para efectuar una perdida de peso
ECSP056159A (es) Composición de fármaco conjugado
WO2006138418A3 (en) Improvement of cognitive performance with sirtuin activators
BRPI0813306A2 (pt) composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
EA200800291A1 (ru) Способы и композиции для лечения офтальмологических состояний
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
WO2005013947A3 (en) Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
AR058621A1 (es) Metodods para reducir la proteina c reactiva
CL2008000303A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure